JOYCLU combines hyaluronic acid and an anti-inflammatory drug, chemically bound using Seikagaku’s proprietary technology. It is designed to release diclofenac by hydrolysis in the joint, and is approved to treat osteoarthritis of the knee and hip via single injection once every four weeks.
Further, since JOYCLU is administered directly into the joint cavity as an injection, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is considered to be low.
JOYCLU combines hyaluronic acid and an anti-inflammatory drug, chemically bound using Seikagaku’s proprietary technology. It is designed to release diclofenac by hydrolysis in the joint, and is approved to treat osteoarthritis of the knee and hip via single injection once every four weeks.
Further, since JOYCLU is administered directly into the joint cavity as an injection, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is considered to be low.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
